Provided by Tiger Trade Technology Pte. Ltd.

Rapport Therapeutics, Inc.

43.62
+0.16000.37%
Post-market: 43.620.00000.00%19:30 EDT
Volume:251.79K
Turnover:10.97M
Market Cap:2.09B
PE:-14.29
High:44.30
Open:44.21
Low:43.01
Close:43.46
52wk High:52.93
52wk Low:22.73
Shares:47.98M
Float Shares:30.39M
Volume Ratio:0.70
T/O Rate:0.83%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.0525
EPS(LYR):-2.8633
ROE:-39.96%
ROA:-25.78%
PB:4.95
PE(LYR):-15.23

Loading ...

Rapport Therapeutics Q2 EPS $(1.19) Misses $(0.96) Estimate

Benzinga Earnings
·
Aug 05

Rapport Therapeutics Q2 FY26 Net Loss Widens to $56.6 Million; R&D Expense More than Doubled to $51.4 Million

Reuters
·
Aug 05

Rapport Therapeutics Reports Second Quarter 2026 Financials and Provides Business Update

THOMSON REUTERS
·
Aug 05

Rapport Therapeutics CEO Abraham Ceesay Sells 2,210 Shares Worth $92,999.37

Reuters
·
Jul 30

William Blair Initiates Rapport Therapeutics at Outperform

MT Newswires Live
·
Jul 28

Rapport Therapeutics initiated with an Outperform at William Blair

TIPRANKS
·
Jul 28

Analysts Offer Insights on NA Companies: CAMP4 Therapeutics Corporation (CAMP), Fiserv (FISV) and Rapport Therapeutics, Inc. (RAPP)

TIPRANKS
·
Jul 28

Goldman Sachs Sticks to Their Buy Rating for Rapport Therapeutics, Inc. (RAPP)

TIPRANKS
·
Jul 22

Analysts Offer Insights on NA Companies: Solv Energy (Nasdaq: MWH), Rapport Therapeutics, Inc. (RAPP) and Volvo Car AB Class B (OtherVLVOF)

TIPRANKS
·
Jul 18

Rapport Therapeutics Price Target Maintained with a $65.00/share by BTIG

Dow Jones
·
Jul 16

Rapport Therapeutics CEO Abraham Ceesay Sells 8,210 Common Shares Worth $328,018

Reuters
·
Jul 16

Rapport Therapeutics management to meet with Citizens

TIPRANKS
·
Jul 16

4x P B For Rapport Therapeutics (RAPP) After Russell Index Additions Looks Pricey

Simply Wall St.
·
Jul 06

Rapport Therapeutics CEO Abraham Ceesay Disposes of Common Shares Worth $327,031.55

Reuters
·
Jul 02

Does Truist’s New RAPP Coverage Subtly Reframe Rapport Therapeutics’ Long-Term Credibility Story (RAPP)?

Simply Wall St.
·
Jun 26

1 Reason Rapport Therapeutics (RAPP) Looks Pricey Following Truist Buy Coverage

Simply Wall St.
·
Jun 25

Rapport Therapeutics Initiated at Outperform by Leerink Partners

Dow Jones
·
Jun 25

Leerink Partners Initiates Rapport Therapeutics at Outperform With $52 Price Target

MT Newswires Live
·
Jun 24

Rapport Therapeutics initiated with an Outperform at Leerink

TIPRANKS
·
Jun 24

Rapport Therapeutics Inc : Leerink Partners Initiates Coverage with Outperform Rating; Price Target $52

THOMSON REUTERS
·
Jun 24